Colorectal adenocarcinoma patients with circ-PRMT1 overexpression were shown to have significantly lower DFS probabilities (p < 0.001) compared to patients with lower circ-PRMT1 levels (Figure 4A). This evidence concerns the gene PRMT1 and colorectal adenocarcinoma.